Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NLX-112 versus placebo for levodopa-induced dyskinesia in Parkinson's disease
2020-006053-22Phase 2Completed
- Sponsor
- Neurolixis
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Befiradol with Placebo (2 arms). Primary endpoint: Adverse events. Started Jul 2021; status: completed.
02
Drugs
NLX-112
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2020-006053-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006053-22.